Catalog No.A2007 Synonyms: Herceptin Non-humanized mouse model applicable
For research use only. Not for use in humans.
Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Choose Selective HER2 Inhibitors
|Description||Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.|
Trastuzumab (anti-HER2) has been demonstrated to exert a variety of anti-tumor effects selectively in HER2-overexpressing tumor cells. Trastuzumab binds to the juxtamembrane domain of HER2 and upon receptor binding, the antibody downregulates the expression of HER2. Trastuzumab selectively blocks ligand-independent HER2-HER3 dimerization. In addition, trastuzumab binding to HER2 blocks proteolytic cleavage of the extracellular domain of HER2, resulting in diminished levels of the more active p95-HER2 form of HER2. As a result of these effects on the HER2 receptor, trastuzumab causes downregulation of PI3K pathway signaling and downstream mediators of cell cycle progression such as cyclin D1. Trastuzumab not only inhibits HER2 signaling pathways but also triggers immune-mediated responses against HER2-overexpressing cells. Trastuzumab binding engages Fc receptors on immune effector cells leading to antibody-dependent cellular cytotoxicity. Beyond these effects, trastuzumab has been shown to have antiangiogenic effects and to lower the proapoptotic threshold for chemotherapy.
|In vivo||Trastuzumab (anti-HER2) is shown to be safe when administered chronically to a range of animals including primates. In experiments mimicking adjuvant therapy of submacroscopic disease in vivo (JIMT-1 cells inoculated s.c. in severe combined immunodeficiency mice), trastuzumab is able to inhibit the outgrowth of macroscopically detectable xenograft tumors for up to 5-7 weeks. Trastuzumab has a remarkable antitumor effect and is currently used worldwide for the treatment of breast cancer. In in vivo models, trastuzumab decreases the microvessel density of breast cancer xenografts. It is well documented that trastuzumab acts directly in cancer cell signaling, as well as indirectly via the immune system.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
If you have any other enquiries, please leave a message.